ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $4.34M rose 46.9% year over year, ahead of the -15.8% change in trailing-twelve-month research & development. Sequentially, it rose 25.9% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.

Context

  • Research & development amounted to 15.6% of revenue in FY2025, down 6.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +46.9% holds above the trailing-twelve-month pace of -15.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.34M+25.9% QoQ
Last fiscal yearDec 2025
$13.18M-32.7% YoY
LTMMar 2026
$14.57M-15.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.9%——
1 year-32.7%——
3-year CAGR-10.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.18M USD
Year-over-year change
-32.7%
4-year CAGR
-10.2%

Research & Development vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 research & development of $14.57M is the lowest of the 4 companies compared; the peer median is $32.2M.
  • Its year-over-year change of -15.8% is the 3rd highest of 4, against a peer median of +26.3%.
  • Research & development amounts to 14.7% of revenue for SPRY, versus a peer median of 20.1%.
SPRY Competitors Peer median
Research & Development for SPRY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNKDMannKind CorporationLTM Mar 2026$72.56M +54.7%+49.8%20.1%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$32.2M +26.3%+14.1%10.2%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.04M -18.6%-0.6%31.9%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$14.57M -15.8%-10.5%14.7%
Peer median (excluding SPRY) $32.2M+26.3%+14.1%20.1%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.